SCHEDULE 13G/A: Aisling Capital Entities Reduce Stake in CalciMedica, Now Below 5% Ownership Threshold
Beneficial Ownership Report Amendment
Aisling Capital entities, including Aisling Capital V, LP, have filed an amendment to their Schedule 13G, indicating their beneficial ownership in CalciMedica, Inc. has decreased to 3.9% of common stock.
Summary
- Aisling Capital V, LP, along with Aisling Capital Partners V, LP, Aisling Capital Partners V LLC, Dr. Andrew Schiff, and Steve Elms, collectively reported beneficial ownership of 781,671 shares of CalciMedica, Inc. common stock.
- This aggregate amount represents 3.9% of CalciMedica's outstanding common stock.
- The ownership consists of 521,114 shares of common stock and presently exercisable warrants to purchase an additional 260,557 shares.
- The percentage ownership is calculated based on 13,481,917 shares of Common Stock outstanding as of November 6, 2024, as reported in CalciMedica's Quarterly Report on Form 10-Q filed on November 13, 2024.
- All reporting persons share both voting and dispositive power over the 781,671 shares.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative as the filing indicates a reduction in beneficial ownership by a significant institutional investor to below the 5% threshold, which can be perceived as a decrease in their conviction.
Negatives
- The filing, an 'Amendment No. 1' to a Schedule 13G, indicates that the Aisling Capital entities' beneficial ownership has fallen below the 5% threshold, suggesting a reduction in their stake from a previously higher level.
- A reduction in ownership by a significant institutional investor like Aisling Capital could be interpreted by the market as a decrease in conviction regarding the company's future prospects.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership changes by an institutional investor in a publicly traded company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders may view the reduction in institutional ownership as a negative signal, potentially influencing investor sentiment and stock price.
Key Dates
| Date | Description |
|---|---|
| 2024-11-06 | Date as of which CalciMedica, Inc.'s common stock outstanding (13,481,917 shares) was reported in its 10-Q. |
| 2024-11-13 | Date CalciMedica, Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 2025-03-03 | Date of event which requires filing of this statement and signature date for all reporting persons. |
Recommendation
holdKeywords
CalciMedica, Aisling Capital, beneficial ownership, Schedule 13G, common stock, warrants, institutional investment, ownership change
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.